SE0100822D0 - Method II to obtain microparticles - Google Patents

Method II to obtain microparticles

Info

Publication number
SE0100822D0
SE0100822D0 SE0100822A SE0100822A SE0100822D0 SE 0100822 D0 SE0100822 D0 SE 0100822D0 SE 0100822 A SE0100822 A SE 0100822A SE 0100822 A SE0100822 A SE 0100822A SE 0100822 D0 SE0100822 D0 SE 0100822D0
Authority
SE
Sweden
Prior art keywords
sup
microparticles
atp
ase inhibitor
obtain microparticles
Prior art date
Application number
SE0100822A
Other languages
English (en)
Swedish (sv)
Inventor
Haakan Glad
Malin Soederblom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100822A priority Critical patent/SE0100822D0/xx
Publication of SE0100822D0 publication Critical patent/SE0100822D0/xx
Priority to SI200230729T priority patent/SI1370243T1/sl
Priority to DK02701872T priority patent/DK1370243T3/da
Priority to PCT/SE2002/000400 priority patent/WO2002072071A1/en
Priority to KR10-2003-7011781A priority patent/KR20030081506A/ko
Priority to CNA028095987A priority patent/CN1507343A/zh
Priority to PT02701872T priority patent/PT1370243E/pt
Priority to HK04102776.2A priority patent/HK1059896B/en
Priority to AU2002235101A priority patent/AU2002235101B8/en
Priority to IL15746702A priority patent/IL157467A0/xx
Priority to JP2002571030A priority patent/JP2004522796A/ja
Priority to MXPA03007887A priority patent/MXPA03007887A/es
Priority to DE60227488T priority patent/DE60227488D1/de
Priority to US10/471,314 priority patent/US20040101565A1/en
Priority to ES02701872T priority patent/ES2307722T3/es
Priority to NZ527997A priority patent/NZ527997A/en
Priority to AT02701872T priority patent/ATE400253T1/de
Priority to EP02701872A priority patent/EP1370243B1/en
Priority to CA002440163A priority patent/CA2440163A1/en
Priority to BR0207827-9A priority patent/BR0207827A/pt
Priority to ZA200306614A priority patent/ZA200306614B/xx
Priority to NO20033966A priority patent/NO20033966L/no
Priority to US11/778,298 priority patent/US20080175917A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
SE0100822A 2001-03-09 2001-03-09 Method II to obtain microparticles SE0100822D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
BR0207827-9A BR0207827A (pt) 2001-03-09 2002-03-06 Método de preparação de uma micropartìcula homogênea que compreende um inibidor de h+/k+-atpase ácido lábil, micropartìcula, composição farmacêutica, método para prevenir ou tratar uma doença relacionada com o ácido gástrico em um mamìfero, e, uso de uma micropartìcula
JP2002571030A JP2004522796A (ja) 2001-03-09 2002-03-06 Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法
DE60227488T DE60227488D1 (de) 2001-03-09 2002-03-06 Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
KR10-2003-7011781A KR20030081506A (ko) 2001-03-09 2002-03-06 Ｈ+, ｋ+ -ａｔｐ-아제 저해제를 함유하는 미립자의 제조방법
CNA028095987A CN1507343A (zh) 2001-03-09 2002-03-06 获得含h+,k+－atp酶抑制剂的微粒的方法
PT02701872T PT1370243E (pt) 2001-03-09 2002-03-06 Método para obter micropartículas contendo um inibidor de h+, k+-atp-ase
HK04102776.2A HK1059896B (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
AU2002235101A AU2002235101B8 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing A H+, K+ -ATP-ase inhibitor
IL15746702A IL157467A0 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+,k+-atp-ase inhibitor
SI200230729T SI1370243T1 (sl) 2001-03-09 2002-03-06 Postopek za pridobivanje mikrodelcev, ki vsebujejo inhibitor H+,K+-ATPaze
MXPA03007887A MXPA03007887A (es) 2001-03-09 2002-03-06 Metodo para obtener microparticulas que contienen inhibidor de h(+), k(+)-atp-asa.
DK02701872T DK1370243T3 (da) 2001-03-09 2002-03-06 Fremgangsmåde til at opnå mikropartikler, der indeholder en H+,K+-ATPase-inhibitor
US10/471,314 US20040101565A1 (en) 2001-03-09 2002-03-06 Mehtod to obtain microparticles containing a h+ k+ atp-ase inhibitor
ES02701872T ES2307722T3 (es) 2001-03-09 2002-03-06 Metodo para obtener microparticulas que contienen un inhibidor de n+,k+atp-asa.
NZ527997A NZ527997A (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a H+, K+ -ATP-ase inhibitor using a fluid-bed granulation technique
AT02701872T ATE400253T1 (de) 2001-03-09 2002-03-06 Verfahren zur gewinnung von mikropartikeln mit a h+, k+ -atp-ase-inhibitor
EP02701872A EP1370243B1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
CA002440163A CA2440163A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
ZA200306614A ZA200306614B (en) 2001-03-09 2003-08-25 Method to obtain microparticles containing a H +, K + -ATP-ase inhibitor.
NO20033966A NO20033966L (no) 2001-03-09 2003-09-08 Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer
US11/778,298 US20080175917A1 (en) 2001-03-09 2007-07-16 Microparticles containing a H+,K+-ATP-ase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles

Publications (1)

Publication Number Publication Date
SE0100822D0 true SE0100822D0 (sv) 2001-03-09

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles

Country Status (21)

Country Link
US (2) US20040101565A1 (enExample)
EP (1) EP1370243B1 (enExample)
JP (1) JP2004522796A (enExample)
KR (1) KR20030081506A (enExample)
CN (1) CN1507343A (enExample)
AT (1) ATE400253T1 (enExample)
AU (1) AU2002235101B8 (enExample)
BR (1) BR0207827A (enExample)
CA (1) CA2440163A1 (enExample)
DE (1) DE60227488D1 (enExample)
DK (1) DK1370243T3 (enExample)
ES (1) ES2307722T3 (enExample)
IL (1) IL157467A0 (enExample)
MX (1) MXPA03007887A (enExample)
NO (1) NO20033966L (enExample)
NZ (1) NZ527997A (enExample)
PT (1) PT1370243E (enExample)
SE (1) SE0100822D0 (enExample)
SI (1) SI1370243T1 (enExample)
WO (1) WO2002072071A1 (enExample)
ZA (1) ZA200306614B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2007095376A2 (en) * 2006-02-15 2007-08-23 Kennametal Inc. Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021153525A1 (ja) * 2020-01-27 2021-08-05 東和薬品株式会社 エソメプラゾール経口製剤およびその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
WO1999018935A1 (de) * 1997-10-15 1999-04-22 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
HUP0100065A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles

Also Published As

Publication number Publication date
IL157467A0 (en) 2004-03-28
WO2002072071A1 (en) 2002-09-19
NO20033966L (no) 2003-11-03
JP2004522796A (ja) 2004-07-29
CA2440163A1 (en) 2002-09-19
AU2002235101B8 (en) 2006-08-31
PT1370243E (pt) 2008-09-16
US20080175917A1 (en) 2008-07-24
ZA200306614B (en) 2004-11-25
AU2002235101B2 (en) 2006-07-13
US20040101565A1 (en) 2004-05-27
ES2307722T3 (es) 2008-12-01
NZ527997A (en) 2005-02-25
SI1370243T1 (sl) 2008-12-31
EP1370243A1 (en) 2003-12-17
EP1370243B1 (en) 2008-07-09
MXPA03007887A (es) 2003-12-04
HK1059896A1 (en) 2004-07-23
ATE400253T1 (de) 2008-07-15
CN1507343A (zh) 2004-06-23
DK1370243T3 (da) 2008-10-13
KR20030081506A (ko) 2003-10-17
NO20033966D0 (no) 2003-09-08
DE60227488D1 (de) 2008-08-21
BR0207827A (pt) 2004-03-02

Similar Documents

Publication Publication Date Title
SE0100822D0 (sv) Method II to obtain microparticles
CY1107488T1 (el) Σταθερα ξηραμενα δια ψεκασμου πρωτεϊνικα σκευασματα
ATE395042T1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
DK459486A (da) Vitaminholdigt granulat, fremstilling deraf og tabletter fremstillet deraf
BR0108058A (pt) Corpo maciço
CY1106015T1 (el) Ενα συμπυκνωμενο, υδατοδιαλυτο, κοκκωδες σκευασμα ρυθμιστη της φυτικης αναπτυξης και μεθοδοι χρησης και ιδιου
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DK0783486T3 (da) Hidtil ukendte prostaglandinsynthaseinhibitorer
AP2003002742A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
TNSN91070A1 (fr) Procede de preparation de derives de benzofuranne, bentothiophene indole ou indolizine ainsi que des compositions les contenant.
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
BR0116969A (pt) método e sistema de gerenciamento de resìduo
DE60238712D1 (de) Tierstreu
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
SE0201659D0 (sv) Modified release pharmaceutical formulation
DE60014875D1 (de) Zementzusammensetzungen
SE0203687D0 (sv) Pharmaceutical Porous Particles
MXPA04005129A (es) Uso de diamina de acido piridin-2,4-dicarboxilico y de diaminas de acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de la colagenasa.
EP1186292A3 (de) Feste Zubereitungen mit einer Multi-Kern Struktur
NZ516620A (en) 1,4-substituted 4,4-diaryl cyclohexanes
FR2840306B1 (fr) Derives d'acide(alkyl d-mannopyranoside) uronique, des procedes pour leur preparation, ainsi que leurs applications
DE60015353D1 (de) 3-oxo-1-propansulfonsäure und -sulfonate